SLP - Simulations Plus, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
19.25
+0.20 (+1.05%)
At close: 4:00PM EDT

19.25 0.00 (0.00%)
After hours: 4:19PM EDT

Stock chart is not supported by your current browser
Previous Close19.05
Open19.00
Bid17.20 x 1100
Ask20.00 x 1300
Day's Range18.95 - 19.45
52 Week Range14.00 - 23.95
Volume37,183
Avg. Volume83,918
Market Cap334.278M
Beta-1.15
PE Ratio (TTM)39.21
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.24 (1.30%)
Ex-Dividend Date2018-07-25
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • ACCESSWIRE25 days ago

    Ex-Dividend Schedule: Simulations Plus Has a Dividend Yield of 1.32%; Will Trade Ex-Dividend on July 25, 2018

    LONDON, UK / ACCESSWIRE / July 24, 2018 / Active-Investors has a free review on Simulations Plus, Inc. (NASDAQ: SLP) following the Company's announcement that it will begin trading ex-dividend on July 25, 2018. To capture the dividend payout, investors must purchase the stock a day prior to the ex-dividend date that is by latest at the end of the trading session on July 24, 2018. Active-Investors has initiated due-diligence on this dividend stock.

  • Business Wire25 days ago

    Simulations Plus Subsidiary DILIsym Awarded Grant for up to $1.7 Million For Model Development

    DILIsym Services, Inc., a Simulations Plus company (SLP) developing in silico modeling software, resources, and information for assisting the pharmaceutical industry to more efficiently develop safe and effective drug therapies, today announced it has been awarded a Fast-Track Small Business Innovation Research (SBIR) grant by the National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK). The grant, coauthored by Dr. Brett Howell (Principal Investigator) and Dr. Bud Nelson, is entitled “Software for predicting a drug’s potential to cause acute kidney injury.” The total award for this Fast Track SBIR grant is up to $1.7 million over the next 18-24 months.

  • Business Wirelast month

    Simulations Plus Enters Funded Research Collaboration with Large European Consortium

    Simulations Plus, Inc. (SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has entered into a one-year funded research collaboration with a large European consortium to further develop and validate the mechanistic Transdermal Compartmental Absorption and Transit (TCAT™) model in GastroPlus™. Dr. Viera Lukacova, director of simulation sciences, said: “We are very pleased to have the opportunity to work with the diverse membership of this large European consortium to enhance the GastroPlus TCAT model in support of alternative approaches to animal testing. The model is already being utilized heavily within pharmaceutical companies to support transdermal product development activities.

  • Business Wirelast month

    Simulations Plus Reports Third Quarter FY2018 Financial Results

    Record quarter as revenues grow 26.7%, 9MoFY18 net income up 63.8%

  • ACCESSWIRElast month

    Simulations Plus, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / July 10, 2018 / Simulations Plus, Inc. (NASDAQ: SLP ) will be discussing their earnings results in their Q3 Earnings Call to be held on July 10, 2018 at 4:15 PM Eastern Time. ...

  • Business Wirelast month

    Company Profile for Simulations Plus, Inc.

    Simulations Plus, Inc., is a premier developer of drug discovery and development software as well as a leading provider of both preclinical and clinical pharmacometric consulting services for regulatory submissions and quantitative systems pharmacology/toxicology models for drug-induced liver injury and nonalcoholic fatty liver disease.

  • Business Wirelast month

    Simulations Plus to Report Third Quarter 2018 Financial Results

    Simulations Plus, Inc. (SLP), announced today that it will report its third quarter financial results for fiscal year 2018, the period ended May 31, 2018, after the close of the financial markets on Tuesday, July 10, 2018. The Company invites all interested persons to attend its conference call at 4:15 p.m. Eastern Time on July 10, 2018. Simulations Plus, Inc., is a premier developer of drug discovery and development software as well as a leading provider of both preclinical and clinical pharmacometric consulting services for regulatory submissions.

  • Business Wire2 months ago

    Simulations Plus Releases ADMET Predictor™ Version 9

    Simulations Plus, Inc. , the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has released version 9 of its flagship artificial intelligence modeling program, ADMET Predictor™.

  • Business Wire2 months ago

    Simulations Plus Names Shawn O’Connor as CEO

    Simulations Plus, Inc. (SLP), the premier provider of simulation and modeling software and consulting services for all stages of pharmaceutical discovery and development, today announced that Shawn M. O’Connor will become its chief executive officer effective June 26, 2018. Mr. O’Connor brings more than three decades of executive experience from multiple industries with companies ranging from start-ups to publicly traded companies and a proven track record for strategy definition, building strong organizations, optimizing revenue, profitability, and cash flow, and creating value for investors.

  • Business Wire3 months ago

    Simulations Plus to Present at the 8th Annual LD Micro Invitational Investor Conference on June 5, 2018

    Simulations Plus, Inc. , the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, and chemical industries, today announced that it will participate in the 8th Annual LD Micro Invitational Investor Conference to be held at the Luxe Sunset Boulevard Hotel in Los Angeles.

  • Business Wire3 months ago

    Simulations Plus Releases GastroPlus™ Version 9.6

    Simulations Plus, Inc. (SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, and chemicals industries, today announced that it has released version 9.6 of its flagship PBPK modeling program, GastroPlus™. With the ever-increasing emphasis on PBPK modeling from regulatory agencies globally, the client base for GastroPlus continues to expand.

  • Business Wire3 months ago

    Simulations Plus to Present at the Needham Emerging Technology Conference on May 16, 2018

    Simulations Plus, Inc. (SLP), the premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development from the earliest discovery through all phases of clinical trials, today announced that chairman and chief executive officer, Walt Woltosz, will present at the Needham Emerging Technology Conference on Wednesday, May 16, 2018, at 3:00 p.m. ET and will conduct one-on-one meetings throughout the day. Simulations Plus, Inc. is a premier developer of drug discovery and development software as well as a leading provider of both preclinical and clinical pharmacometric consulting services for regulatory submissions. The company is a global leader focused on improving the ways scientists use knowledge and data to predict the properties and outcomes of pharmaceutical and biotechnology agents.

  • Business Wire3 months ago

    US FDA Procures DILIsym Software License Package

    DILIsym Services, Inc., a Simulations Plus company (SLP) and a leading provider of simulation and modeling software for pharmaceutical safety, today announced that the U.S. Food and Drug Administration has secured an annual government license for its flagship QSP (quantitative systems pharmacology) modeling software, DILIsym®. DILIsym is the product of an ongoing public-private partnership (the DILI-sim Initiative – www.DILIsym.com) that involves scientists from the pharmaceutical industry, academia and the FDA. The use of modeling and simulation tools like DILIsym is being promoted by FDA Commissioner Dr. Scott Gottlieb to improve the efficiency of drug development (https://blogs.fda.gov/fdavoice/index.php/2017/06/fostering-medical-innovation-a-plan-for-digital-health-devices/).

  • ACCESSWIRE4 months ago

    EX-Dividend Schedule: Simulations Plus Has a Dividend Yield of 1.38%; Will Trade Ex-Dividend on April 24, 2018

    LONDON, UK / ACCESSWIRE / April 20, 2018 / Active-Investors has a free review on Simulations Plus, Inc. (NASDAQ: SLP) following the Company's announcement that it will begin trading ex-dividend on April 24, 2018. Active-Investors has initiated due-diligence on this dividend stock. If your portfolio includes dividend stocks, you have come to the right place for timely information.

  • Business Wire4 months ago

    Simulations Plus Reports Record Second Quarter FY2018 Revenue

    Simulations Plus, Inc. , the premier provider of simulation and modeling software and consulting services for all stages of pharmaceutical discovery and development from the earliest discovery through all phases of clinical trials, today reported financial results for its second quarter of fiscal year 2018, the period ended February 28, 2018 .

  • ACCESSWIRE4 months ago

    Simulations Plus, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / April 9, 2018 / Simulations Plus, Inc. (NASDAQ: SLP ) will be discussing their earnings results in their Q2 Earnings Call to be held on April 9, 2018, at 4:15 PM Eastern Time. ...

  • Business Wire4 months ago

    Simulations Plus Sets Date for 2nd Quarter 2018 Earnings Release and Conference Call

    Simulations Plus, Inc. announced today that it expects to file its quarterly report on Form 10-Q for the second quarter of its 2018 fiscal year, the period ended February 28, 2018, on Monday, April 9, 2018.

  • Business Wire6 months ago

    Simulations Plus Launches Version 2.0 of PKPlus™

    Simulations Plus, Inc. , the premier provider of simulation and modeling software and consulting services for pharmaceutical development from earliest discovery through all phases of clinical trials, today announced the launch of version 2.0 of PKPlus, a major update to its software for analysis of preclinical and clinical trial data.

  • Business Wire7 months ago

    Simulations Plus Subsidiary Cognigen Releases KIWI Version 2

    Cognigen Corporation, a Simulations Plus company and a leading provider of population pharmacokinetic and pharmacodynamic modeling and simulation services, today announced that it has released Version 2 of its KIWI™ Pharmacometric Communication and Collaboration Platform.

  • ACCESSWIRE7 months ago

    EX-Dividend Schedule: Simulations Plus Has a Dividend Yield of 1.47%; Will Trade Ex-Dividend on January 25, 2018

    LONDON, UK / ACCESSWIRE / January 24, 2018 / Active-Investors has a free review on Simulations Plus, Inc. (NASDAQ: SLP ) following the Company's announcement that it will begin trading ex-dividend on January ...

  • Business Wire7 months ago

    Simulations Plus Announces Quarterly Cash Dividend of $0.06 per Share

    Simulations Plus, Inc. , the premier provider of simulation and modeling software and consulting services for all stages of pharmaceutical discovery and development, today announced that its board of directors has declared its next ongoing quarterly cash dividend of $0.06 per share to its shareholders.

  • ACCESSWIRE7 months ago

    Free Post Earnings Research Report: Bandwidth’s Revenue Grew 7%; Beats Expectations

    Stock Monitor: Simulations Plus Post Earnings Reporting LONDON, UK / ACCESSWIRE / January 16, 2018 / Active-Investors.com has just released a free earnings report on Bandwidth Inc. (NASDAQ: BAND ). If ...

  • Business Wire7 months ago

    DILIsym Services Inc., a Simulations Plus Company, Releases DILIsym® Version 7A

    DILIsym Service, Inc., a Simulations Plus company and a leading provider of simulation and modeling software for pharmaceutical safety and efficacy, today announced that it has released Version 7A of its flagship QSP modeling program, DILIsym®.

  • Business Wire7 months ago

    Simulations Plus Reports First Quarter FY2018 Financial Results

    Simulations Plus, Inc. , the premier provider of simulation and modeling software and consulting services for all stages of pharmaceutical discovery and development from the earliest discovery through all phases of clinical trials, today reported financial results for its first quarter of fiscal year 2018, the period ended November 30, 2017 .